PharmTech spoke with Tara Dougal, event director for pharma at Informa Markets, about trends impacting the pharmaceutical industry and how CPHI Milan is addressing these areas this year.
News|Articles|August 12, 2016
New NIH Grant to Focus on AIDS Vaccine Characterization and Manufacturing
Author(s)Pharmaceutical Technology Editors
The work will focus on addressing a key bottleneck to progress: he complexity and instability of HIV envelope proteins, which has limited the amount of material that can be evaluated in clinical trials.
Advertisement
A $98-million, seven-year contract will fund work to improve manufacturing, at the International AIDS Vaccine Initiative
The US National Institutes of Health’s National Institute of Allergy and Infectious Diseases, has awarded the International AIDS Vaccine Initiative (IAVI) a $98-million, seven-year contract to help speed the development of AIDS vaccine candidates.
The contract covers a range of product development services to advance the characterization and manufacturing of HIV envelope protein immunogens, which has been a focus of IAVI’s research efforts.
Manufacturing of these immunogens has proven difficult, given the complexity and instability of HIV envelope proteins. This has limited the amount of material that can be evaluated in clinical trials. Optimizing HIV vaccine manufacturing would accelerate the development and evaluation of promising candidates.
IAVI and NIAID have been partnering closely in AIDS vaccine research for many years, including in the design and development of HIV envelope immunogens designed to trigger protective antibody responses.
Source:
Advertisement
Related to this article
Andrew Parker, PhD, executive drug development consultant, Quotient Sciences, explains how AI is integrated into pharmaceutical development.
PDA/FDA 2026 session maps the GMP audit lifecycle, root cause to CAPA closure, plus a local vs. above-site decision framework and two case studies.
The recently opened NJ spray drying facility doubles capacity for amorphous solid dispersions, addressing solubility limits in roughly 70% of small-molecule pipelines.
Lori Dingledine, QC Director Microbiological Control and GTIC Operations at Genentech, provided input on the regulations surrounding raw material manufacturing and use for ATMPs in a presentation at the 2026 PDA/FDA Joint Regulatory Conference.
FDA opens applications for its Expedited IND Pilot, pairing sponsors with qualified research institutions to test rolling CMC review ahead of first-in-human trials.
2026 approvals, clinical data, and licensing deals are advancing subcutaneous biologics, reducing patient burden, and reshaping biopharma drug strategy.
Karthik Iyer, Eli Lilly, details an AI system linking GMP findings, audits, and deviations for cited, inspection-ready regulatory intelligence.
Advertisement
Advertisement